JP2020523038A5 - - Google Patents

Download PDF

Info

Publication number
JP2020523038A5
JP2020523038A5 JP2020518571A JP2020518571A JP2020523038A5 JP 2020523038 A5 JP2020523038 A5 JP 2020523038A5 JP 2020518571 A JP2020518571 A JP 2020518571A JP 2020518571 A JP2020518571 A JP 2020518571A JP 2020523038 A5 JP2020523038 A5 JP 2020523038A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
cells
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020518571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523038A (ja
JP7679196B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/065237 external-priority patent/WO2018224682A1/en
Publication of JP2020523038A publication Critical patent/JP2020523038A/ja
Publication of JP2020523038A5 publication Critical patent/JP2020523038A5/ja
Priority to JP2023097445A priority Critical patent/JP7596447B2/ja
Priority to JP2024205869A priority patent/JP2025028972A/ja
Application granted granted Critical
Publication of JP7679196B2 publication Critical patent/JP7679196B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020518571A 2017-06-08 2018-06-08 Cd38調節抗体 Active JP7679196B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023097445A JP7596447B2 (ja) 2017-06-08 2023-06-14 Cd38調節抗体
JP2024205869A JP2025028972A (ja) 2017-06-08 2024-11-27 Cd38調節抗体

Applications Claiming Priority (33)

Application Number Priority Date Filing Date Title
US201762517149P 2017-06-08 2017-06-08
US201762517150P 2017-06-08 2017-06-08
US62/517,149 2017-06-08
US62/517,150 2017-06-08
US201762517745P 2017-06-09 2017-06-09
US201762517165P 2017-06-09 2017-06-09
US201762517753P 2017-06-09 2017-06-09
US201762517740P 2017-06-09 2017-06-09
US201762517164P 2017-06-09 2017-06-09
US201762517734P 2017-06-09 2017-06-09
US62/517,734 2017-06-09
US62/517,165 2017-06-09
US62/517,745 2017-06-09
US62/517,740 2017-06-09
US62/517,753 2017-06-09
US62/517,164 2017-06-09
US201762546322P 2017-08-16 2017-08-16
US201762546330P 2017-08-16 2017-08-16
US62/546,330 2017-08-16
US62/546,322 2017-08-16
US201762582616P 2017-11-07 2017-11-07
US201762582676P 2017-11-07 2017-11-07
US201762582681P 2017-11-07 2017-11-07
US201762582653P 2017-11-07 2017-11-07
US201762582666P 2017-11-07 2017-11-07
US201762582628P 2017-11-07 2017-11-07
US62/582,628 2017-11-07
US62/582,681 2017-11-07
US62/582,616 2017-11-07
US62/582,653 2017-11-07
US62/582,676 2017-11-07
US62/582,666 2017-11-07
PCT/EP2018/065237 WO2018224682A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097445A Division JP7596447B2 (ja) 2017-06-08 2023-06-14 Cd38調節抗体

Publications (3)

Publication Number Publication Date
JP2020523038A JP2020523038A (ja) 2020-08-06
JP2020523038A5 true JP2020523038A5 (enExample) 2021-07-26
JP7679196B2 JP7679196B2 (ja) 2025-05-19

Family

ID=62620845

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020518571A Active JP7679196B2 (ja) 2017-06-08 2018-06-08 Cd38調節抗体
JP2023097445A Active JP7596447B2 (ja) 2017-06-08 2023-06-14 Cd38調節抗体
JP2024205869A Pending JP2025028972A (ja) 2017-06-08 2024-11-27 Cd38調節抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023097445A Active JP7596447B2 (ja) 2017-06-08 2023-06-14 Cd38調節抗体
JP2024205869A Pending JP2025028972A (ja) 2017-06-08 2024-11-27 Cd38調節抗体

Country Status (8)

Country Link
US (2) US11780930B2 (enExample)
EP (1) EP3635001A1 (enExample)
JP (3) JP7679196B2 (enExample)
CN (2) CN111051344B (enExample)
AU (2) AU2018280868B2 (enExample)
CA (1) CA3066547A1 (enExample)
NZ (1) NZ759835A (enExample)
WO (1) WO2018224682A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
CA3126735A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
WO2021062184A1 (en) * 2019-09-26 2021-04-01 Orionis Biosciences, Inc. Pd-l1 targeted chimeric proteins and uses thereof
CN114616245B (zh) * 2019-12-13 2024-02-23 山东先声生物制药有限公司 一种抗cd38的抗体及其用途
JP7720871B2 (ja) * 2020-06-23 2025-08-08 ジアンスー カニョン ファーマシューティカル カンパニー リミテッド 抗cd38抗体及びその使用
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业(上海)股份有限公司 结合人cd38的抗体、其制备方法和用途
CA3190385A1 (en) * 2020-09-10 2022-03-17 Alexander Anthony Zukiwski Methods of blood screening
CN114437215B (zh) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 抗人cd38抗体及其制备方法和用途
KR20250130398A (ko) * 2023-01-05 2025-09-01 다나-파버 캔서 인스티튜트 인크. Cd38 세포-표면 수용체의 에피토프 조작
WO2025166138A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + tslp targeting antibodies and uses thereof
WO2025166146A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + ox40 targeting antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗cd38ヒト抗体及びその用途
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
AR053489A1 (es) 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
JP5362359B2 (ja) 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトCD38に特異的な完全ヒトHuCALGOLD由来の治療抗体の生成とプロファイリング
AU2013209322A1 (en) * 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
CN101605906A (zh) * 2006-12-14 2009-12-16 梅达雷克斯公司 结合cd70的人类抗体及其用途
CA2697193C (en) 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2743361C (en) * 2008-10-06 2021-05-25 Neil R. Cashman Methods and systems for predicting misfolded protein epitopes
SG178925A1 (en) 2009-09-22 2012-04-27 Volker Sandig Process for producing molecules containing specialized glycan structures
WO2012009568A2 (en) 2010-07-16 2012-01-19 Adimab, Llc Antibody libraries
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ, エルエルシー 細胞外標的化薬物共役体
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016164656A1 (en) 2015-04-08 2016-10-13 Sorrento Therapeutics, Inc. Antibody therapeutics that bind cd38
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
HUE066300T2 (hu) * 2015-06-24 2024-07-28 Janssen Biotech Inc Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
US10358497B2 (en) 2015-09-29 2019-07-23 Amgen Inc. Methods of treating cardiovascular disease with an ASGR inhibitor
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체

Similar Documents

Publication Publication Date Title
JP2020523038A5 (enExample)
EP3668898B1 (en) Humanized antibodies for cd3
CN110914306B (zh) 检查点抑制物双特异性抗体
Shepard et al. Developments in therapy with monoclonal antibodies and related proteins
JP2024050684A (ja) 腫瘍特異的細胞枯渇のためのFc最適化抗CD25
JP2022050618A5 (enExample)
JP2016505556A5 (enExample)
JP2020515247A5 (enExample)
RU2018114523A (ru) Анти-tigit антитела и способы применения
JPWO2019175226A5 (enExample)
JP2020531043A (ja) 抗4−1bb抗体とその作製及び使用方法
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
JP2019514347A5 (enExample)
RS65904B1 (sr) Polipeptidi koji regrutuju t ćelije na osnovu reaktivnosti cd3
JPWO2019175215A5 (enExample)
JPWO2019175216A5 (enExample)
JPWO2019175223A5 (enExample)
JPWO2019175224A5 (enExample)
CA3185846A1 (en) Anti-cd70 antibody and application thereof
AU2024202109A1 (en) Combinations and uses thereof
US20240026018A1 (en) Antibodies for t-cell activation
US20220213203A1 (en) Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic Malignancies
JP2023530720A (ja) Lewis Yに対するヒト化抗体
RU2020128108A (ru) Антитело против cd25 для опухоль-специфической клеточной деплеции
JPWO2022072601A5 (enExample)